Top Markets
Coin of the day
Egetis Therapeutics AB (publ) Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

EGTX
Clasificación en acciones #14551
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to... Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
Precio por acción
$0.87679425
Última sincronización: 2026-08-31
Capitalización bursátil
$407.66M
Cambio (1 día)
-1.88%
Cambio (1 año)
58.03%
País
SE
Comercio Egetis Therapeutics AB (publ) (EGTX)

Categoría

Ratio P/S de Egetis Therapeutics AB (publ) (EGTX)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Egetis Therapeutics AB (publ), el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Egetis Therapeutics AB (publ) desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
10.95 -
US
12.19 -
NL
3.75 -
AU
24.99 -
US
- -
CH